黑色素瘤辅助治疗:临床试验与真实世界的对比
本研究基于荷兰DMTR人群登记数据库,分析了641例接受辅助抗PD-1治疗的黑色素瘤患者。真实世界中毒性率和提前停药率略高于临床试验,但无复发生存率相似。
要点
- 真实世界辅助抗PD-1治疗12个月RFS为70.6%(95%CI 66.9-74.6)。
- 性别、疾病分期和Breslow厚度与RFS风险升高相关。
核心结论
- 真实世界辅助抗PD-1治疗切除后III/IV期黑色素瘤的RFS与临床试验相似,但毒性和提前停药率略高。
研究设计与样本
- 基于荷兰DMTR人群登记数据库的回顾性分析,纳入641例接受辅助抗PD-1治疗的黑色素瘤患者。
主要发现
- 12个月RFS为70.6%(95%CI 66.9-74.6),中位随访12.8个月。
- 性别、疾病分期和Breslow厚度与RFS风险升高相关。
临床怎么用
- 真实世界辅助抗PD-1治疗需关注毒性管理和提前停药风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about outcomes of adjuvant-treated melanoma patients beyond the clinical trial setting. Since 2019, adjuvant-treated melanoma patients have been registered in the DMTR, a population-based registry to monitor the quality and safety of melanoma care in the Netherlands. This study aims to describe treatment patterns, relapse, and toxicity rates of adjuvant-treated melanoma patients beyond the clinical trial setting. METHODS: Analyses were performed on adjuvant-treated melanoma patients included in the DMTR. Descriptive statistics were used to analyse patient-, and treatment characteristics. A baseline registration completeness analysis was performed, and an analysis on trial eligibility in clinical practice patients. Recurrence-free survival (RFS) at 12-months was estimated with the Kaplan-Meier method. RESULTS: A total of 641 patients were treated with adjuvant anti-PD-1 therapy. RFS at 12-months was 70.6% (95% CI, 66.9-74.6) with a median follow-up of 12.8 months. Sex, stage of disease and Breslow thickness were associated with a higher hazard for RFS. Eighteen per cent of the anti-PD-1-treated patients developed grade ≥3 toxicity. Sixty-one per cent of patients prematurely discontinued anti-PD-1 therapy. CONCLUSION: Adjuvant anti-PD-1 treatment of resected stage III/IV melanoma in daily practice showed slightly higher toxicity rates and more frequent premature discontinuation but similar RFS rates compared to trials.
引用
- de Meza MM, Ismail RK, Rauwerdink D, et al. Adjuvant treatment for melanoma in clinical practice - Trial versus reality. Eur J Cancer. 2021. PMID: 34600790. doi:10.1016/j.ejca.2021.08.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。